GASTROENTEROLOGY
Transforming IBD monitoring with at-home calprotectin testing
A recent pilot study examined at-home faecal calprotectin testing for IBD patients, using a digitally integrated, patient-led model and a quantitative lateral flow calprotectin assay. Graham Johnson details the study and looks at the benefits offered by such a pathway.
Despite ongoing therapeutic advances, inflammatory bowel disease (IBD) continues to pose a significant clinical and logistical challenge for the NHS. Over half a million people in the UK alone live with Crohn’s disease and ulcerative colitis,1 both of which are chronic conditions that require lifelong monitoring and swift intervention during flare-ups. For many, symptom flares arise unpredictably and often escalate quickly, carrying a heavy toll on quality of life. However, delays in diagnosis and treatment remain common, exacerbated by the limitations of traditional laboratory testing pathways. To address this issue, an innovative multidisciplinary team at University Hospital Southampton (UHS) NHS Foundation Trust has pioneered a digitally integrated, patient-led model using at- home faecal calprotectin testing. Over the course of 12 months, this approach has demonstrated improved disease management, faster decision-making, greater patient engagement and reduced strain on outpatient services. IBD is marked by episodes of active inflammation in the gastrointestinal tract, often leading to abdominal pain, diarrhoea, fatigue and other debilitating symptoms. These flares are not only disruptive to patients’ lives, they also carry a steep financial burden. Each flare may lead to urgent clinical intervention, diagnostic testing, hospital admission or therapeutic escalation, placing a heavy load on already stretched services and costing the NHS over £10,500 per patient per year.2
While long-term biologic 36
WWW.PATHOLOGYINPRACTICE.COM February 2026
therapies have significantly improved disease control,3
patients taking these
medications require close monitoring for efficacy and the risk of adverse effects. For instance, gastrointestinal inflammation can be assessed non-invasively by measuring faecal calprotectin, a highly specific and sensitive biomarker secreted by neutrophils during mucosal inflammation and excreted in stool.
Importantly, elevated levels of calprotectin can precede clinical symptoms,4
offering
a valuable window for therapeutic escalation to prevent worsening disease. Despite its clinical utility, access to
rapid calprotectin testing is often limited by the constraints of conventional laboratory processing. Traditionally, patients suspected of having a flare up were required to submit a stool sample for
Elevated levels of calprotectin can precede clinical symptoms, offering a valuable window for therapeutic escalation to prevent worsening disease.
AdobeStock / Witoon
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
